Not applicableNo Longer AvailableNCT02451852What this trial is testingAZD9291 US Expanded Access ProgramWho this might be right forEGFR T790M Mutation Positive NSCLC AstraZeneca
Large-scale testing (Phase 3)Active Not RecruitingNCT03521154What this trial is testingA Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)Who this might be right forNon Small Cell Lung Cancer (Stage III) AstraZeneca 216
Early research (Phase 1)Study completedNCT02529995What this trial is testingPhase I, Study in Chinese NSCLC PatientsWho this might be right forCarcinoma, Non-Small-Cell Lung With EGFR Mutation Positive AstraZeneca 31
Testing effectiveness (Phase 2)Looking for participantsNCT07231068What this trial is testingA Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR MutationWho this might be right forNon-Small Cell Lung Cancer Henan Genuine Biotech Co., Ltd. 153
Testing effectiveness (Phase 2)Ended earlyNCT03784599What this trial is testingT-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLCWho this might be right forCarcinoma, Non-Small-Cell Lung The Netherlands Cancer Institute 28
Not applicableStudy completedNCT04207775What this trial is testingReal World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI TherapyWho this might be right forLocally Advanced or Metastatic NSCLC AstraZeneca 300
Testing effectiveness (Phase 2)Study completedNCT03513666What this trial is testingToripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI TreatmentWho this might be right forNSCLC Shanghai Junshi Bioscience Co., Ltd. 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07256509What this trial is testingSYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer CSPC Megalith Biopharmaceutical Co.,Ltd. 120
Not applicableStudy completedNCT03137264What this trial is testingResistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive PatientsWho this might be right forNon-small Cell Lung Cancer AstraZeneca 44
Testing effectiveness (Phase 2)Study completedNCT02444819What this trial is testingPhase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer TherapyWho this might be right forNon Small Cell Lung Cancer Hanmi Pharmaceutical Company Limited 33
Testing effectiveness (Phase 2)Looking for participantsNCT07304739What this trial is testingFurmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesWho this might be right forNon Small Cell Lung Cancer Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT06192849What this trial is testingTo Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant ChemotherapyWho this might be right forNon Small Cell Lung CancerEGFR Exon 20 Insertion Mutation Juan LI, MD 20
Large-scale testing (Phase 3)UnknownNCT03866499What this trial is testingBPI-7711 Capsule in Non-small Cell Lung Cancer PatientsWho this might be right forNSCLC Beta Pharma Shanghai 369
Testing effectiveness (Phase 2)Looking for participantsNCT07314216What this trial is testingFirmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary AdenocarcinomaWho this might be right forNSCLC (Non-small Cell Lung Carcinoma)Stage IIIEGFR Uncommon Mutations Hunan Cancer Hospital 15
Testing effectiveness (Phase 2)Looking for participantsNCT03175224What this trial is testingAPL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsWho this might be right forSolid TumorsAdvanced CancerRenal Cancer+15 more Apollomics Inc. 497
Not applicableStudy completedNCT03370770What this trial is testingAfatinib Osimertinib Sequencing NISWho this might be right forCarcinoma, Non-Small-Cell Lung Boehringer Ingelheim 204
Large-scale testing (Phase 3)Active Not RecruitingNCT02411448What this trial is testingRamucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)Who this might be right forMetastatic Non-Small Cell Lung Cancer Eli Lilly and Company 545
Large-scale testing (Phase 3)Not Yet RecruitingNCT06048315What this trial is testingA Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal AntibodyWho this might be right forLung CancerTKI ResistanceEGFR Sensitive Mutation+2 more Degan Lu 52
Large-scale testing (Phase 3)Active Not RecruitingNCT04351555What this trial is testingOsimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer AstraZeneca 358
Large-scale testing (Phase 3)Active Not RecruitingNCT02511106What this trial is testingAZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.Who this might be right forStage IB-IIIA Non-small Cell Lung Carcinoma AstraZeneca 682